S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
257. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon
D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation
adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J
Radiat Oncol Biol Phys 2001;50(5):1243-52.
http://www.ncbi.nlm.nih.gov/pubmed/11483335
258. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy
and sequencing of a short course of androgen suppression on freedom from biochemical
failure when administered with radiation therapy for T2-T3 prostate cancer. Journal of
Urology 2004;171(3):1137-40. http://www.ncbi.nlm.nih.gov/pubmed/14767287
259. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant
hormone therapy for localised and locally advanced prostate cancer. Cochrane Database
Syst Rev 2006;(4):CD006019. http://www.ncbi.nlm.nih.gov/pubmed/17054269
260. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following
radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a
prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14(6):1085-91.
http://www.ncbi.nlm.nih.gov/pubmed/3133327
261. Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C.
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or
locally advanced prostate cancer: results from the randomised Early Prostate Cancer
Programme. Radiother Oncol 2005;76(1):4-10.
http://www.ncbi.nlm.nih.gov/pubmed/16145740
262. Granfors T, Modig H, Damber JE, Tomic R. Long-term followup of a randomized study of
locally advanced prostate cancer treated with combined orchiectomy and external
radiotherapy versus radiotherapy alone. Journal of Urology 2006;176(2):544-7.
http://www.ncbi.nlm.nih.gov/pubmed/16813885
263. See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly
improves overall survival in men with locally advanced prostate cancer. J Cancer Res Clin
Oncol 2006;132 Suppl 1:S7-16. http://www.ncbi.nlm.nih.gov/pubmed/16896884
264. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and metaanalysis
of randomised trials of neo-adjuvant hormone therapy for localised and locally
advanced prostate carcinoma. Cancer Treat Rev 2009;35(1):9-17.
http://www.ncbi.nlm.nih.gov/pubmed/18926640
265. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I,
Hoyer M, Wiklund F, Fossa SD. Endocrine treatment, with or without radiotherapy, in locally
advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet
2009;373(9660):301-8. http://www.ncbi.nlm.nih.gov/pubmed/19091394
266. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone therapy for
localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of
randomised trials. Cancer Treat Rev 2009;35(7):540-6.
http://www.ncbi.nlm.nih.gov/pubmed/19493624
267. Roach M, III, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D,
Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam
radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin
Oncol 2008;26(4):585-91. http://www.ncbi.nlm.nih.gov/pubmed/18172188
268. Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nistico C, Ruggeri EM, Sperduti I,
Bracarda S, Pinnaro P, Lanzetta G, Muti P, Cognetti F, Carlini P. Impact of hormonal
treatment duration in combination with radiotherapy for locally advanced prostate cancer:
meta-analysis of randomized trials. BMC Cancer 2010;10:675.
http://www.ncbi.nlm.nih.gov/pubmed/21143897
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011